Buscar en
Annals of Hepatology
Toda la web
Inicio Annals of Hepatology P-57 LIVER STEATOSIS AND STEATOHEPATITIS IN LIVER DISEASES OTHER THAN ALCOHOLIC ...
Journal Information
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Share
Share
Download PDF
More article options
Vol. 24. Issue S1.
Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)
(September 2021)
Open Access
P-57 LIVER STEATOSIS AND STEATOHEPATITIS IN LIVER DISEASES OTHER THAN ALCOHOLIC AND NON-ALCOHOLIC FATTY LIVER
Visits
540
Ana Jiménez1, Felipe Contreras1, Miguel Leiva José1, Nicolás Moreno1, Claudio Altschiller1, Andrea Jimenez1, Alvaro Urzúa1, Maximo Cattaneo1, Laura Carreño2, Juan Pablo Roblero1, Jaime Poniachik1
1 Sección de Gastroenterología, Departamento de Medicina Interna, Hospital Clínico Universidad de Chile, Santiago, Chile
2 Departamento de Anatomía Patológica, Hospital Clínico Universidad de Chile, Santiago, Chile
This item has received

Under a Creative Commons license
Article information
Special issue
This article is part of special issue:
Vol. 24. Issue S1

Abstracts of the 2021 Annual meeting of the ALEH (Asociación Latinoamericana para el Estudio del Hígado)

More info
Introduction

Fatty liver disease (FLD) alcoholic and non-alcoholic are prevalent conditions. The damage is determined by steatosis and steatohepatitis with or without fibrosis. There is little information on its role in the progression to significant fibrosis (SF) of chronic liver diseases (CLD) other than FLD.

Objective

To describe the frequency of steatosis and steatohepatitis in liver biopsies of patients with CLD other than FLD.

Methods

Observational, retrospective study with biopsies performed between 2015-2018. The presence and degree of steatosis, steatohepatitis and fibrosis were recorded according to the METAVIR scale; F3-F4 is considered SF.

Results

268 biopsies analyzed; 93 with FLD are excluded. 175 are included: 53% autoimmune hepatitis (AIH), 27% primary biliary cholangitis (PBC), 7% viral hepatitis (VH) and 13% others. 74% women; age 52 (18-82) years; 58% had steatosis and 46% had steatohepatitis; 67% fibrosis, which was SF in 61%. Steatosis/steatohepatitis/fibrosis according to etiology: AIH 34%/46%/69%; PBC 19%/9%/53%; VH 77%/15%/39%. When analyzing the presence of SF according to the presence of steatosis or steatohepatitis: in steatosis 36% vs 48% without steatosis; In steatohepatitis there were more SF (65% vs 36%; p = 0.004). According to aetiology SF/non SF: HAI 92%/38% (p = 0.001); PBC 20%/24%; VH 50%/22% (NS).

Conclusion

There was a high frequency of steatosis and steatohepatitis in patients with CLD. The presence of steatohepatitis is associated with a higher degree of fibrosis in patients with CLD, particularly in AIH, which may have an impact on the evolution and treatment.

Full text is only aviable in PDF
Article options
Tools
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
10.1016/j.aohep.2021.100423
No mostrar más